Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A few more steps ahead
August 2017
SHARING OPTIONS:

CAMBRIDGE, U.K.—Horizon Discovery Group plc recently announced that it has advanced its gene and cell therapy platform for contract service and therapeutic applications. Specific details were not released, but a company press release noted that the new offering will leverage Horizon's gene-editing technologies, including CRISPR and its rAAV and Transposon technologies, to edit pluripotent stem cell and primary human lymphocytes.
 
The company is working with three clients to support preclinical development across a variety of gene and cell therapy treatments in fields with high unmet need. Horizon noted in a press release that its research biotech business intends to leverage its intellectual property and expertise to develop a universal cell therapy platform for companies developing autologous and allogeneic cell therapy projects in areas such as immuno-oncology, autoimmune diseases, rare genetic diseases, metabolic, neurological and blood disorders.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.